|Day Low/High||4.73 / 4.97|
|52 Wk Low/High||3.35 / 11.65|
Investors in Insys Therapeutics Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 16th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $12.75, changing hands for $13.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.
Investors in Insys Therapeutics Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Proof-of-concept study aims to assess efficacy, safety, tolerability and pharmacokinetics of company's novel CBD product candidate
Using standard intramuscular injection as comparator, company's Phase 1 clinical trial enrolls first patient
Novel formulation of partial opioid offers potential benefits compared to current alternatives
Investors in Insys Therapeutics Inc saw new options become available this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
Official Launch of SYNDROS® and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insys Therapeutics, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors eyeing a purchase of Insys Therapeutics Inc shares, but cautious about paying the going market price of $7.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $6 strike, which has a bid at the time of this writing of 45 cents.
The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
Extension of Expanded Access Program Enables Patients from Initial Trials to Continue Taking Investigational Medicine Under Their Physicians' Supervision
Results Show Favorable Effect of Company's Novel Formulation, Similar to Intramuscular Administration; NDA Filing with FDA on Track for 2018
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.